2022 World Conference on Lung Cancer (ePosters)-EP08.02-097. Prevalence, Clinical Characteristics and Survival of Patients With Brain Metastases and KRAS Mutation Lung Cancer in Argentina

EP08.02-097. Prevalence, Clinical Characteristics and Survival of Patients With Brain Metastases and KRAS Mutation Lung Cancer in Argentina

Back to course

Pdf Summary

This study focuses on the clinical features and outcomes of patients with KRAS gene mutations (KRASm) in lung adenocarcinomas. The study found that 20% of lung adenocarcinomas harbor KRASm, with the most prevalent mutation being KRAS G12C. The study also looked at the response to immunotherapy treatments, finding that the overall response rate (ORR) was 51% and the disease control rate (DCR) was 77%. The median overall survival was 26 months.<br /><br />One specific focus of the study was brain metastasis in patients with KRASm lung cancer. The prevalence of brain metastases at diagnosis was found to be 25%. For patients with central nervous system (CNS) involvement, the median survival was 11 months, significantly lower than the general population. Additionally, 40% of patients developed CNS involvement during the course of the disease.<br /><br />Among patients without brain metastases at diagnosis, 22% experienced CNS progression, with a median time to brain progression of 10.5 months from diagnosis. The median number of brain metastases was 3, with the most frequent site being cerebellar involvement in 33% of cases.<br /><br />Factors associated with a worse prognosis for patients with brain metastases included the location and number of brain metastases, as well as a negative level of PD-L1. Treatment options for brain metastases included surgery (38% of cases) and radiosurgery (27% of cases).<br /><br />In summary, this study provides insights into the clinical features and outcomes of patients with KRASm lung cancer, particularly focusing on brain metastasis. It highlights the prevalence and impact of brain metastases, as well as factors associated with prognosis and treatment options.

Asset Subtitle

Luis Basbus

Meta Tag

Speaker Luis Basbus

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

KRAS gene mutations

lung adenocarcinomas

KRAS G12C

immunotherapy treatments

brain metastasis

CNS involvement

median survival

CNS progression

number of brain metastases

treatment options